Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling:  ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.  

On August 8^th 2025, the U.S. Food and Drug Administration (FDA)  accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.

 

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

 

For more information, please visit www.arvinas.com. 

Position Summary

The internship project will explore approaches to ternary complex modeling and have a focus on evaluating internal, commercial, and literature workflows and tools. Collaborating closely with members of the Arvinas CADD team, the intern will configure, run, and benchmark ternary complex modeling workflows. The intern will present results at CADD team meetings and will summarize their work as a talk or poster at Arvinas at the conclusion of the internship.

This position reports to the Senior Research Investigator, Computational Chemistry and can be located remotely within the U.S.

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

• Explore state of the art tools for protein structure prediction and ternary complex modeling.
• Collect and prepare a comprehensive dataset of published ternary complex X-ray and cryo-EM structures.
• Rigorously evaluate the performance of different ternary complex modeling approaches.
• Prepare and present results at an internal Arvinas function at the conclusion of the internship.

Qualifications

• Experience using protein structure predictions methods (AlphaFold, RoseTTAFold, Boltz, etc.) is required.
• Experience with a cheminformatics toolkit (RDKit, OpenEye, Schrodinger, etc.) is required.
• Proficiency in Python programming required.
• Experience using version control (GitHub, GitLab, Bitbucket, etc.) required.
• Knowledge of and experience with at least one ML framework (TensorFlow, PyTorch or Keras) is desirable.
• Experience working on medicinal chemistry projects is desirable.
• Must be able to work effectively in both independent and team contexts.
• Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship.
• The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours.

 

EDUCATION

• Computational Chemistry/Biology, Chemistry, Biology, or Computer Science major.
• Completion of classes in Computational Chemistry, Chemistry, and/or Molecular Biology & Biophysics strongly preferred.
• Preference for doctoral graduate students nearing degree completion.

#LI-Remote

 

Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com

Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.